Skip to main content
Erschienen in: Journal of Genetic Counseling 1/2017

09.06.2016 | Original Research

The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program

verfasst von: A. E. Bunnell, C. A. Garby, E. J. Pearson, S. A. Walker, L. E. Panos, Joanne L. Blum

Erschienen in: Journal of Genetic Counseling | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Since the 2013 Supreme Court ruling on BRCA1/BRCA2 patenting, hereditary cancer gene panels now include BRCA1 and BRCA2, making these panels an option for first-tier testing. However, questions remain about the clinical utility and implications of these panels for medical management with inclusion of genes of unknown to moderate penetrance. To better understand how use of these panels affected our practice, we reviewed patients who underwent testing in our clinic from July 1, 2013 through May 23, 2014. Indications for testing included personal and/or family history of breast and/or ovarian cancer. A total of 136 patients underwent panel testing via a single commercial laboratory; 12 (8.8 %) patients were positive for a pathogenic or likely pathogenic mutation (four BRCA2 mutations, two TP53 mutations, one CDH1 mutation, two ATM mutations, and one patient each with a CHEK2, NBN, or PALB2 mutation). Of these positive patients, 100 % met the National Comprehensive Cancer Network (NCCN) guidelines for Hereditary Breast and Ovarian Cancer genetic testing (2.2014). Mutations in seven of twelve (58 %) patients led to changes in medical management; three of seven (43 %) had a non-BRCA1 or BRCA2 gene mutation. Our findings suggest that there is clinical utility of panels that include genes of unknown to moderate penetrance.
Literatur
Zurück zum Zitat Breast Cancer Linkage, C. (1999). Cancer risks in BRCA2 mutation carriers. Journal of the National Cancer Institute, 91(15), 1310–1316.CrossRef Breast Cancer Linkage, C. (1999). Cancer risks in BRCA2 mutation carriers. Journal of the National Cancer Institute, 91(15), 1310–1316.CrossRef
Zurück zum Zitat Couch, F. J., Nathanson, K. L., & Offit, K. (2014). Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science, 343(6178), 1466–1470.CrossRefPubMedPubMedCentral Couch, F. J., Nathanson, K. L., & Offit, K. (2014). Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science, 343(6178), 1466–1470.CrossRefPubMedPubMedCentral
Zurück zum Zitat Daly, M. B., Pilarski, R., Axilbund, J. E., Buys, S. S., Crawford, B., Friedman, S., et al. (2014). Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. Journal of the National Comprehensive Cancer Network, 12(9), 1326–1338.PubMed Daly, M. B., Pilarski, R., Axilbund, J. E., Buys, S. S., Crawford, B., Friedman, S., et al. (2014). Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. Journal of the National Comprehensive Cancer Network, 12(9), 1326–1338.PubMed
Zurück zum Zitat Debniak, T., Gorski, B., Cybulski, C., Jakubowska, A., Kurzawski, G., Lener, M., et al. (2003). Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin. Melanoma Research, 13(4), 365–370.CrossRefPubMed Debniak, T., Gorski, B., Cybulski, C., Jakubowska, A., Kurzawski, G., Lener, M., et al. (2003). Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin. Melanoma Research, 13(4), 365–370.CrossRefPubMed
Zurück zum Zitat Doherty, J., Bonadies, D. C., & Matloff, E. T. (2015). Testing for hereditary breast cancer: panel or targeted testing? Experience from a clinical cancer genetics practice. Journal of Genetic Counseling, 24(4), 683–687.CrossRefPubMed Doherty, J., Bonadies, D. C., & Matloff, E. T. (2015). Testing for hereditary breast cancer: panel or targeted testing? Experience from a clinical cancer genetics practice. Journal of Genetic Counseling, 24(4), 683–687.CrossRefPubMed
Zurück zum Zitat Domchek, S. M., Bradbury, A., Garber, J. E., Offit, K., & Robson, M. E. (2013). Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? Journal of Clinical Oncology, 31(10), 1267–1270.CrossRefPubMed Domchek, S. M., Bradbury, A., Garber, J. E., Offit, K., & Robson, M. E. (2013). Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? Journal of Clinical Oncology, 31(10), 1267–1270.CrossRefPubMed
Zurück zum Zitat Easton, D. F., Pharoah, P. D., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., et al. (2015). Gene-panel sequencing and the prediction of breast-cancer risk. The New England Journal of Medicine, 372(23), 2243–2257.CrossRefPubMedPubMedCentral Easton, D. F., Pharoah, P. D., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., et al. (2015). Gene-panel sequencing and the prediction of breast-cancer risk. The New England Journal of Medicine, 372(23), 2243–2257.CrossRefPubMedPubMedCentral
Zurück zum Zitat Friedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., et al. (1994). Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genetics, 8(4), 399–404.CrossRefPubMed Friedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., et al. (1994). Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genetics, 8(4), 399–404.CrossRefPubMed
Zurück zum Zitat Gabai-Kapara, E., Lahad, A., Kaufman, B., Friedman, E., Segev, S., Renbaum, P., et al. (2014). Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proceedings of the National Academy of Sciences of the United States of America, 111(39), 14205–14210.CrossRefPubMedPubMedCentral Gabai-Kapara, E., Lahad, A., Kaufman, B., Friedman, E., Segev, S., Renbaum, P., et al. (2014). Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proceedings of the National Academy of Sciences of the United States of America, 111(39), 14205–14210.CrossRefPubMedPubMedCentral
Zurück zum Zitat Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 2.2014. (2014). National Comprehensive Cancer Network. Retrieved from www.nccn.org Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 2.2014. (2014). National Comprehensive Cancer Network. Retrieved from www.nccn.org
Zurück zum Zitat Gumaste, P. V., Penn, L. A., Cymerman, R. M., Kirchhoff, T., Polsky, D., & McLellan, B. (2015). Skin cancer risk in BRCA1/2 mutation carriers. The British Journal of Dermatology, 172(6), 1498–1506.CrossRefPubMed Gumaste, P. V., Penn, L. A., Cymerman, R. M., Kirchhoff, T., Polsky, D., & McLellan, B. (2015). Skin cancer risk in BRCA1/2 mutation carriers. The British Journal of Dermatology, 172(6), 1498–1506.CrossRefPubMed
Zurück zum Zitat Katz, S. J., Kurian, A. W., & Morrow, M. (2015). Treatment decision making and genetic testing for breast cancer: mainstreaming mutations. JAMA, 314(10), 997–998.CrossRefPubMed Katz, S. J., Kurian, A. W., & Morrow, M. (2015). Treatment decision making and genetic testing for breast cancer: mainstreaming mutations. JAMA, 314(10), 997–998.CrossRefPubMed
Zurück zum Zitat Kean, S. (2014). Breast cancer. The 'other' breast cancer genes. Science, 343(6178), 1457–1459.CrossRefPubMed Kean, S. (2014). Breast cancer. The 'other' breast cancer genes. Science, 343(6178), 1457–1459.CrossRefPubMed
Zurück zum Zitat Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., et al. (2014). Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. Journal of Clinical Oncology, 32(19), 2001–2009.CrossRefPubMedPubMedCentral Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., et al. (2014). Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. Journal of Clinical Oncology, 32(19), 2001–2009.CrossRefPubMedPubMedCentral
Zurück zum Zitat Rainville, I. R., & Rana, H. Q. (2014). Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Current Oncology Reports, 16(3), 371.CrossRefPubMed Rainville, I. R., & Rana, H. Q. (2014). Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Current Oncology Reports, 16(3), 371.CrossRefPubMed
Zurück zum Zitat Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA: a Cancer Journal for Clinicians, 65(1), 5–29. Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA: a Cancer Journal for Clinicians, 65(1), 5–29.
Zurück zum Zitat Steffen, J., Varon, R., Mosor, M., Maneva, G., Maurer, M., Stumm, M., et al. (2004). Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. International Journal of Cancer, 111(1), 67–71.CrossRefPubMed Steffen, J., Varon, R., Mosor, M., Maneva, G., Maurer, M., Stumm, M., et al. (2004). Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. International Journal of Cancer, 111(1), 67–71.CrossRefPubMed
Zurück zum Zitat Susswein, L. R., Marshall, M. L., Nusbaum, R., Vogel Postula, K. J., Weissman, S. M., Yackowski, L., et al. (2015). Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genetics in Medicine. doi:10.1038/gim.2015.166. Susswein, L. R., Marshall, M. L., Nusbaum, R., Vogel Postula, K. J., Weissman, S. M., Yackowski, L., et al. (2015). Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genetics in Medicine. doi:10.​1038/​gim.​2015.​166.
Zurück zum Zitat Tedaldi, G., Danesi, R., Zampiga, V., Tebaldi, M., Bedei, L., Zoli, W., et al. (2014). First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer. BMC Cancer, 14, 478.CrossRefPubMedPubMedCentral Tedaldi, G., Danesi, R., Zampiga, V., Tebaldi, M., Bedei, L., Zoli, W., et al. (2014). First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer. BMC Cancer, 14, 478.CrossRefPubMedPubMedCentral
Zurück zum Zitat Turner, J., Kelly, B., Clarke, D., Yates, P., Aranda, S., Jolley, D., et al. (2011). A randomised trial of a psychosocial intervention for cancer patients integrated into routine care: the PROMPT study (promoting optimal outcomes in mood through tailored psychosocial therapies). BMC Cancer, 11, 48.CrossRefPubMedPubMedCentral Turner, J., Kelly, B., Clarke, D., Yates, P., Aranda, S., Jolley, D., et al. (2011). A randomised trial of a psychosocial intervention for cancer patients integrated into routine care: the PROMPT study (promoting optimal outcomes in mood through tailored psychosocial therapies). BMC Cancer, 11, 48.CrossRefPubMedPubMedCentral
Zurück zum Zitat Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., et al. (2006). Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA, 295(12), 1379–1388.CrossRefPubMed Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., et al. (2006). Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA, 295(12), 1379–1388.CrossRefPubMed
Zurück zum Zitat Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., et al. (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 107(28), 12629–12633.CrossRefPubMedPubMedCentral Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., et al. (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 107(28), 12629–12633.CrossRefPubMedPubMedCentral
Zurück zum Zitat Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108(44), 18032–18037.CrossRefPubMedPubMedCentral Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 108(44), 18032–18037.CrossRefPubMedPubMedCentral
Zurück zum Zitat Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559), 789–792.CrossRefPubMed Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature, 378(6559), 789–792.CrossRefPubMed
Metadaten
Titel
The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program
verfasst von
A. E. Bunnell
C. A. Garby
E. J. Pearson
S. A. Walker
L. E. Panos
Joanne L. Blum
Publikationsdatum
09.06.2016
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 1/2017
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-016-9985-2

Weitere Artikel der Ausgabe 1/2017

Journal of Genetic Counseling 1/2017 Zur Ausgabe

ACKNOWLEDGMENTS

Thank You to Reviewers

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.